Created by researchers at the University of British Columbia, the Index of Cannabis Equivalence creates a standardized framework for lower doses of cannabis.
As legalization and use of cannabis increases in Canada, a recently published study looked to establish a standard cannabis dose. As noted in the abstract, a standard dose could be useful in regulation, substance use guidelines, data collection, research, and also for self-monitoring and as a customary way to communicate low-risk recommendations and dose-related effects. The study “The Index of Cannabis Equivalence (ICE): A User-Centered Approach to Standardization of Cannabis Dose–Response” was published in the Journal of Psychoactive Drugs in January 2025 and received funding from Social Sciences and Humanities Research Council of Canada (SSHRC).
This study focused on tolerance and mode of ingestion, more so than most studies, which focused on cannabinoid content.
“Different cannabis consumption methods can produce varied psychoactive effects, which makes it difficult to establish comparable doses across products,” explains Dr. Michelle St. Pierre, co-author of the study, in a news release from the University of British Columbia (UBC) Okanagan Campus (2). “The ICE addresses this challenge by providing user-informed equivalencies grounded in psychoactive effects, offering a practical framework to help individuals make informed decisions and better manage their cannabis use.”
It involved 1368 participants (42% were female) between the ages of 18 – 93, and all of whom had used cannabis in the past. The resulting The Index of Cannabis Equivalence (ICE) was created and established the following equivalents of a “low-dose” of cannabis: “two puffs on a joint, pipe, herbal or concentrate vaporizer is equivalent to one hit on a bong, a 5 mg/THC edible, and ¼ dab of a concentrate” (1).
The abstract noted that the ability to generalize these results to a population with high tolerance may be limited, as they were based on participants who had reported lower tolerance. The researchers also concluded that, “The meaningful standardization of units of cannabis products in a manner similar to what has been achieved for alcohol represents a valuable step in establishing standard doses across different modes of cannabis administration.”
“By creating practical and user-centred guidelines, the ICE can support harm reduction, public health initiatives and consumer education while improving consistency in research and policy,” says Dr. Zach Walsh of UBCO’s Department of Psychology, co-author of the study.
Dr. Walsh and Dr. St. Pierre conduct research at the Therapeutic, Recreational and Problematic Substance Use Lab at UBC. One of their recent studies examined patient perspectives when approaching the therapeutic use of psychedelics with their physicians (3).
References
New Study Finds Cannabinoids May Offer A Safer Pain Relief Option Without Addiction Risks
January 31st 2025Yale researchers investigated in a recent study how cannabinoids can be used as an alternative chronic pain treatment without addiction risks and found that they can help lower pain signals in Nav1.8.
Best of the Week: January 24 - January 30, 2025
January 31st 2025Here, we bring you our top four recent news articles, covering the cannabis and hemp beverage industry trends, cannabis hyperemesis syndrome, and research studies on brain function after cannabis use and on cannabis for inflammatory bowel disease.